UnitedHealth (UNH) 10-Q 3 May 23 2023 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information Document - shares	3 Months Ended
	Mar. 31, 2023	Apr. 28, 2023
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Mar. 31, 2023
Document Transition Report	false
Entity File Number	1-10864
Entitiy Registrant Name	UnitedHealth Group Incorporated
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	41-1321939
Entity Address, Address Line One	UnitedHealth Group Center
Entity Address, Address Line Two	9900 Bren Road East
Entity Address, City or Town	Minnetonka,
Entity Address, State or Province	MN
Entity Address, Postal Zip Code	55343
City Area Code	952
Local Phone Number	936-1300
Title of 12(b) Security	Common Stock, $.01 par value
Trading Symbol	UNH
Security Exchange Name	NYSE
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entitiy Central Index Key	0000731766
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q1
Amendment Flag	false
Entity Common Stock, Shares Outstanding		931,032,030

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) shares in Millions, $ in Millions	Mar. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 41,913	$ 23,365
Short-term investments	4,584	4,546
Accounts receivable, net	22,414	17,681
Other current receivables, net	14,696	12,769
Assets under management	3,837	4,087
Prepaid expenses and other current assets	6,451	6,621
Total current assets	93,895	69,069
Long-term investments	46,884	43,728
Property, equipment and capitalized software, net	10,637	10,128
Goodwill	100,406	93,352
Other intangible assets, net	16,165	14,401
Other assets	15,692	15,027
Total assets	283,679	245,705
Current liabilities:
Medical costs payable	31,809	29,056
Accounts payable and accrued liabilities	29,856	27,715
Short-term borrowings and current maturities of long-term debt	9,931	3,110
Unearned revenues	14,487	3,075
Other current liabilities	30,399	26,281
Total current liabilities	116,482	89,237
Long-term debt, less current maturities	60,657	54,513
Deferred income taxes	2,834	2,769
Other liabilities	13,084	12,839
Total liabilities	193,057	159,358
Commitments and contingencies (Note 6)
Redeemable noncontrolling interests	4,801	4,897
Equity:
Preferred stock, $0.001 par value - 10 shares authorized; no shares issued or outstanding	0	0
Common stock, $0.01 par value - 3,000 shares authorized; 932 and 934 issued and outstanding	9	9
Retained earnings	88,852	86,156
Accumulated other comprehensive loss	(7,549)	(8,393)
Nonredeemable noncontrolling interests	4,509	3,678
Total equity	85,821	81,450
Total liabilities, redeemable noncontrolling interests and equity	$ 283,679	$ 245,705
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	10	10
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	3,000	3,000
Common stock, shares issued	932	934
Common stock, shares outstanding	932	934

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations - USD ($) shares in Millions, $ in Millions	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Revenues:
Premiums	$ 72,786	$ 64,070
Investment and other income	798	367
Total revenues	91,931	80,149
Operating costs:
Medical costs	59,845	52,523
Operating costs	13,625	11,401
Cost of products sold	9,405	8,487
Depreciation and amortization	970	788
Total operating costs	83,845	73,199
Earnings from operations	8,086	6,950
Interest expense	(754)	(433)
Earnings before income taxes	7,332	6,517
Provision for income taxes	(1,558)	(1,369)
Net earnings	5,774	5,148
Earnings attributable to noncontrolling interests	(163)	(121)
Net earnings attributable to UnitedHealth Group common shareholders	$ 5,611	$ 5,027
Earnings per share attributable to UnitedHealth Group common shareholders:
Basic	$ 6.01	$ 5.34
Diluted	$ 5.95	$ 5.27
Basic weighted-average number of common shares outstanding	933	941
Dilutive effect of common share equivalents	10	13
Diluted weighted-average number of common shares outstanding	943	954
Anti-dilutive shares excluded from the calculation of dilutive effect of common share equivalents	5	2
Products
Revenue from Products and Services	$ 10,267	$ 9,340
Services
Revenue from Products and Services	$ 8,080	$ 6,372

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Comprehensive Income - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Net earnings	$ 5,774	$ 5,148
Other comprehensive income (loss):
Gross unrealized gains (losses) on investment securities during the period	640	(2,023)
Income tax effect	(147)	465
Total unrealized gains (losses), net of tax	493	(1,558)
Gross reclassification adjustment for net realized losses (gains) included in net earnings	13	(3)
Income tax effect	(3)	1
Total reclassification adjustment, net of tax	10	(2)
Total foreign currency translation gains	341	918
Other comprehensive income (loss)	844	(642)
Comprehensive income	6,618	4,506
Comprehensive income attributable to noncontrolling interests	(163)	(121)
Comprehensive income attributable to UnitedHealth Group common shareholders	$ 6,455	$ 4,385

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Changes in Equity - USD ($) shares in Millions, $ in Millions	Total	Common Stock [Member]	Additional Paid-In Capital [Member]	Retained Earnings [Member]	Net Unrealized Gains (Losses) on Investments [Member]	Foreign Currency Translation Losses [Member]	Nonredeemable Noncontrolling Interests [Member]
Balance at Dec. 31, 2021	$ 75,045	$ 10	$ 0	$ 77,134	$ 423	$ (5,807)	$ 3,285
Balance (in shares) at Dec. 31, 2021		941
Net earnings attributable to UnitedHealth Group common shareholders	5,027			5,027
Net earnings attributable to nonredeemable noncontrolling interest							88
Net Earnings, Including Portion Attributable to Nonredeemable Noncontrolling Interest	5,115
Other comprehensive income (loss)	(642)				(1,560)	918
Issuances of common stock, and related tax effects (in shares)		3
Issuances of common stock, and related tax effects	333	$ 0	333
Share-based compensation	282		282
Common share repurchases (in shares)		(5)
Common share repurchases	(2,500)	$ 0	(484)	(2,016)
Cash dividends paid on common shares	(1,363)			(1,363)
Redeemable noncontrolling interests fair value and other adjustments	(131)		(131)
Acquisition and other adjustments of nonredeemable noncontrolling interests	91						91
Distribution to nonredeemable noncontrolling interests	(102)						(102)
Balance at Mar. 31, 2022	76,128	$ 10	0	78,782	(1,137)	(4,889)	3,362
Balance (in shares) at Mar. 31, 2022		939
Balance at Dec. 31, 2022	$ 81,450	$ 9	0	86,156	(2,778)	(5,615)	3,678
Balance (in shares) at Dec. 31, 2022	934	934
Net earnings attributable to UnitedHealth Group common shareholders	$ 5,611			5,611
Net earnings attributable to nonredeemable noncontrolling interest							113
Net Earnings, Including Portion Attributable to Nonredeemable Noncontrolling Interest	5,724
Other comprehensive income (loss)	844				503	341
Issuances of common stock, and related tax effects (in shares)		2
Issuances of common stock, and related tax effects	350	$ 0	350
Share-based compensation	366		366
Common share repurchases (in shares)		(4)
Common share repurchases	(2,011)	$ 0	(633)	(1,378)
Cash dividends paid on common shares	(1,537)			(1,537)
Redeemable noncontrolling interests fair value and other adjustments	(83)		(83)
Acquisition and other adjustments of nonredeemable noncontrolling interests	819						819
Distribution to nonredeemable noncontrolling interests	(101)						(101)
Balance at Mar. 31, 2023	$ 85,821	$ 9	$ 0	$ 88,852	$ (2,275)	$ (5,274)	$ 4,509
Balance (in shares) at Mar. 31, 2023	932	932

Condensed Consolidated Statem_4

Condensed Consolidated Statement of Changes in Equity (Parenthetical) - $ / shares	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Statement of Stockholders' Equity [Abstract]
Common Stock, Dividends, Per Share, Cash Paid	$ 1.65	$ 1.45

Condensed Consolidated Statem_5

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Operating activities
Net earnings	$ 5,774	$ 5,148
Noncash items:
Depreciation and amortization	970	788
Deferred income taxes	(332)	161
Share-based compensation	362	299
Other, net	69	17
Net change in other operating items, net of effects from acquisitions and changes in AARP balances:
Accounts receivable	(4,306)	(4,521)
Other assets	(1,875)	(1,089)
Medical costs payable	2,467	3,849
Accounts payable and other liabilities	1,796	589
Unearned revenues	11,402	78
Cash flows from operating activities	16,327	5,319
Investing activities
Purchases of investments	(4,894)	(4,982)
Sales of investments	456	1,591
Maturities of investments	2,119	1,759
Cash paid for acquisitions, net of cash assumed	(7,826)	(1,231)
Purchases of property, equipment and capitalized software	(760)	(555)
Other, net	(115)	(255)
Cash flows used for investing activities	(11,020)	(3,673)
Financing activities
Common share repurchases	(2,000)	(2,500)
Cash dividends paid	(1,537)	(1,363)
Proceeds from common stock issuances	344	551
Repayments of long-term debt	(1,375)	(1,100)
Proceeds from short-term borrowings, net	7,349	3,148
Proceeds from issuance of long-term debt	6,401	0
Customer funds administered	5,012	5,120
Other, net	(1,004)	(1,552)
Cash flows from financing activities	13,190	2,304
Effect of exchange rate changes on cash and cash equivalents	51	157
Increase in cash and cash equivalents	18,548	4,107
Cash and cash equivalents, beginning of period	23,365	21,375
Cash and cash equivalents, end of period	$ 41,913	$ 25,482

Basis of Presentation (Notes)

Basis of Presentation (Notes)	3 Months Ended
	Mar. 31, 2023
Basis of Presentation and Significant Accounting Policies [Text Block]	Basis of Presentation UnitedHealth Group Incorporated (individually and together with its subsidiaries, “UnitedHealth Group” and the “Company”) is a health care and well-being company with a mission to help people live healthier lives and help make the health system work better for everyone. Our two distinct, yet complementary business platforms — Optum and UnitedHealthcare — are working to help build a modern, high-performing health system through improved access, affordability, outcomes and experiences for the individuals and organizations the Company is privileged to serve. The Company has prepared the Condensed Consolidated Financial Statements according to U.S. Generally Accepted Accounting Principles (GAAP) and has included the accounts of UnitedHealth Group and its subsidiaries. The year-end condensed consolidated balance sheet was derived from audited financial statements, but does not include all disclosures required by GAAP. In accordance with the rules and regulations of the U.S. Securities and Exchange Commission (SEC), the Company has omitted certain footnote disclosures that would substantially duplicate the disclosures contained in its annual audited Consolidated Financial Statements. Therefore, these Condensed Consolidated Financial Statements should be read together with the Consolidated Financial Statements and the Notes included in Part II, Item 8, “Financial Statements and Supplementary Data” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022 as filed with the SEC (2022 10-K). The accompanying Condensed Consolidated Financial Statements include all normal recurring adjustments necessary to present the interim financial statements fairly. Use of Estimates These Condensed Consolidated Financial Statements include certain amounts based on the Company’s best estimates and judgments. The Company’s most significant estimates relate to estimates and judgments for medical costs payable and goodwill. Certain of these estimates require the application of complex assumptions and judgments, often because they involve matters that are inherently uncertain and will likely change in subsequent periods. The impact of any change in estimates is included in earnings in the period in which the estimate is adjusted. Revenues - Products and Services

Investments (Notes)

Investments (Notes)	3 Months Ended
	Mar. 31, 2023
Investments [Abstract]
Investments [Text Block]	Investments A summary of debt securities by major security type is as follows: (in millions) Amortized Gross Gross Fair March 31, 2023 Debt securities - available-for-sale: U.S. government and agency obligations $ 4,760 $ 5 $ (236) $ 4,529 State and municipal obligations 8,055 65 (365) 7,755 Corporate obligations 24,149 59 (1,525) 22,683 U.S. agency mortgage-backed securities 8,213 35 (708) 7,540 Non-U.S. agency mortgage-backed securities 3,156 1 (283) 2,874 Total debt securities - available-for-sale 48,333 165 (3,117) 45,381 Debt securities - held-to-maturity: U.S. government and agency obligations 594 — (10) 584 State and municipal obligations 28 — (3) 25 Corporate obligations 60 — — 60 Total debt securities - held-to-maturity 682 — (13) 669 Total debt securities $ 49,015 $ 165 $ (3,130) $ 46,050 December 31, 2022 Debt securities - available-for-sale: U.S. government and agency obligations $ 4,093 $ 1 $ (285) $ 3,809 State and municipal obligations 7,702 25 (479) 7,248 Corporate obligations 23,675 17 (1,798) 21,894 U.S. agency mortgage-backed securities 7,379 15 (808) 6,586 Non-U.S. agency mortgage-backed securities 3,077 1 (294) 2,784 Total debt securities - available-for-sale 45,926 59 (3,664) 42,321 Debt securities - held-to-maturity: U.S. government and agency obligations 578 — (14) 564 State and municipal obligations 29 — (3) 26 Corporate obligations 89 — — 89 Total debt securities - held-to-maturity 696 — (17) 679 Total debt securities $ 46,622 $ 59 $ (3,681) $ 43,000 The Company held $3.9 billion and $3.7 billion of equity securities as of March 31, 2023 and December 31, 2022, respectively. The Company’s investments in equity securities primarily consist of employee savings plan related investments, venture investments and shares of Brazilian real denominated fixed-income funds with readily determinable fair values. Additionally, the Company’s investments included $1.5 billion of equity method investments in operating businesses in the health care sector as of March 31, 2023 and December 31, 2022. The allowance for credit losses on held-to-maturity securities at March 31, 2023 and December 31, 2022 was not material. The amortized cost and fair value of debt securities as of March 31, 2023, by contractual maturity, were as follows: Available-for-Sale Held-to-Maturity (in millions) Amortized Fair Amortized Fair Due in one year or less $ 4,722 $ 4,691 $ 377 $ 376 Due after one year through five years 14,356 13,708 261 254 Due after five years through ten years 12,240 11,217 24 22 Due after ten years 5,646 5,351 20 17 U.S. agency mortgage-backed securities 8,213 7,540 — — Non-U.S. agency mortgage-backed securities 3,156 2,874 — — Total debt securities $ 48,333 $ 45,381 $ 682 $ 669 The fair value of available-for-sale debt securities with gross unrealized losses by major security type and length of time that individual securities have been in a continuous unrealized loss position were as follows: Less Than 12 Months 12 Months or Greater Total (in millions) Fair Gross Fair Gross Fair Gross March 31, 2023 Debt securities - available-for-sale: U.S. government and agency obligations $ 1,279 $ (12) $ 1,825 $ (224) $ 3,104 $ (236) State and municipal obligations 1,898 (30) 3,110 (335) 5,008 (365) Corporate obligations 6,337 (178) 12,443 (1,347) 18,780 (1,525) U.S. agency mortgage-backed securities 1,589 (55) 4,274 (653) 5,863 (708) Non-U.S. agency mortgage-backed securities 783 (26) 1,989 (257) 2,772 (283) Total debt securities - available-for-sale $ 11,886 $ (301) $ 23,641 $ (2,816) $ 35,527 $ (3,117) December 31, 2022 Debt securities - available-for-sale: U.S. government and agency obligations $ 2,007 $ (96) $ 1,290 $ (189) $ 3,297 $ (285) State and municipal obligations 4,630 (288) 1,178 (191) 5,808 (479) Corporate obligations 13,003 (893) 6,637 (905) 19,640 (1,798) U.S. agency mortgage-backed securities 3,561 (345) 2,239 (463) 5,800 (808) Non-U.S. agency mortgage-backed securities 1,698 (128) 976 (166) 2,674 (294) Total debt securities - available-for-sale $ 24,899 $ (1,750) $ 12,320 $ (1,914) $ 37,219 $ (3,664) The Company’s unrealized losses from debt securities as of March 31, 2023 were generated from approximately 32,000 positions out of a total of 42,000 positions. The Company believes that it will collect the timely principal and interest due on its debt securities that have an amortized cost in excess of fair value. The unrealized losses were primarily caused by interest rate increases and not by unfavorable changes in the credit quality associated with these securities which impacted the Company’s assessment on collectability of principal and interest. At each reporting period, the Company evaluates available-for-sale debt securities for any credit-related impairment when the fair value of the investment is less than its amortized cost. The Company evaluated the expected cash flows, the underlying credit quality and credit ratings of the issuers noting no significant credit deterioration since purchase. As of March 31, 2023, the Company did not have the intent to sell any of the available-for-sale debt securities in an unrealized loss position. Therefore, the Company believes these losses to be temporary. The allowance for credit losses on available-for-sale debt securities at March 31, 2023 and December 31, 2022 was not material.

Fair Value (Notes)

Fair Value (Notes)	3 Months Ended
	Mar. 31, 2023
Fair Value Disclosures [Abstract]
Fair Value [Text Block]	Fair Value Certain assets and liabilities are measured at fair value in the Condensed Consolidated Financial Statements or have fair values disclosed in the Notes to the Condensed Consolidated Financial Statements. These assets and liabilities are classified into one of three levels of a hierarchy defined by GAAP. For a description of the methods and assumptions that are used to estimate the fair value and determine the fair value hierarchy classification of each class of financial instrument, see Note 4 of Notes to the Consolidated Financial Statements included in Part II, Item 8, “Financial Statements and Supplementary Data” in the 2022 10-K. The following table presents a summary of fair value measurements by level and carrying values for items measured at fair value on a recurring basis in the Condensed Consolidated Balance Sheets: (in millions) Quoted Prices Other Unobservable Total March 31, 2023 Cash and cash equivalents $ 41,851 $ 62 $ — $ 41,913 Debt securities - available-for-sale: U.S. government and agency obligations 4,122 407 — 4,529 State and municipal obligations — 7,755 — 7,755 Corporate obligations 16 22,486 181 22,683 U.S. agency mortgage-backed securities — 7,540 — 7,540 Non-U.S. agency mortgage-backed securities — 2,874 — 2,874 Total debt securities - available-for-sale 4,138 41,062 181 45,381 Equity securities 2,128 35 70 2,233 Assets under management 1,491 2,245 101 3,837 Total assets at fair value $ 49,608 $ 43,404 $ 352 $ 93,364 Percentage of total assets at fair value 53 % 46 % 1 % 100 % December 31, 2022 Cash and cash equivalents $ 23,202 $ 163 $ — $ 23,365 Debt securities - available-for-sale: U.S. government and agency obligations 3,505 304 — 3,809 State and municipal obligations — 7,248 — 7,248 Corporate obligations 7 21,695 192 21,894 U.S. agency mortgage-backed securities — 6,586 — 6,586 Non-U.S. agency mortgage-backed securities — 2,784 — 2,784 Total debt securities - available-for-sale 3,512 38,617 192 42,321 Equity securities 2,043 35 70 2,148 Assets under management 1,788 2,203 96 4,087 Total assets at fair value $ 30,545 $ 41,018 $ 358 $ 71,921 Percentage of total assets at fair value 42 % 57 % 1 % 100 % There were no transfers in or out of Level 3 financial assets or liabilities during the three months ended March 31, 2023 or 2022. The following table presents a summary of fair value measurements by level and carrying values for certain financial instruments not measured at fair value on a recurring basis in the Condensed Consolidated Balance Sheets: (in millions) Quoted Prices Other Unobservable Total Total Carrying Value March 31, 2023 Debt securities - held-to-maturity $ 595 $ 74 $ — $ 669 $ 682 Long-term debt and other financing obligations $ — $ 60,307 $ — $ 60,307 $ 62,360 December 31, 2022 Debt securities - held-to-maturity $ 577 $ 102 $ — $ 679 $ 696 Long-term debt and other financing obligations $ — $ 53,626 $ — $ 53,626 $ 56,823 Nonfinancial assets and liabilities or financial assets and liabilities that are measured at fair value on a nonrecurring basis are subject to fair value adjustments only in certain circumstances, such as when the Company records an impairment. There were no significant fair value adjustments for these assets and liabilities recorded during the three months ended March 31, 2023 or 2022.

Medical Costs Payable (Notes)

Medical Costs Payable (Notes)	3 Months Ended
	Mar. 31, 2023
Insurance [Abstract]
Short-Duration Insurance and Deposit Contracts	Medical Costs Payable The following table shows the components of the change in medical costs payable for the three months ended March 31: (in millions) 2023 2022 Medical costs payable, beginning of period $ 29,056 $ 24,483 Acquisitions 1 8 Reported medical costs: Current year 60,315 52,813 Prior years (470) (290) Total reported medical costs 59,845 52,523 Medical payments: Payments for current year (35,087) (29,589) Payments for prior years (22,006) (18,749) Total medical payments (57,093) (48,338) Medical costs payable, end of period $ 31,809 $ 28,676

Short-Term Borrowings and Long-

Short-Term Borrowings and Long-Term Debt (Notes)	3 Months Ended
	Mar. 31, 2023
Debt Disclosure [Abstract]
Debt Disclosure	Short-Term Borrowings and Long-Term Debt In March 2023, the Company issued $6.5 billion of senior unsecured notes consisting of the following: (in millions, except percentages) Par Value 4.250% notes due January 2029 $ 1,250 4.500% notes due April 2033 1,500 5.050% notes due April 2053 2,000 5.200% notes due April 2063 1,750 As of March 31, 2023, the Company had $8.2 billion of commercial paper outstanding, with a weighted-average annual interest rate of 5.2%. For more information on the Company’s short-term borrowings, debt covenants and long-term debt, see Note 8 of Notes to the Consolidated Financial Statements included in Part II, Item 8, “Financial Statements and Supplementary Data” in the 2022 10-K.

Commitments and Contingencies (

Commitments and Contingencies (Notes)	3 Months Ended
	Mar. 31, 2023
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies Disclosure [Text Block]	Commitments and Contingencies Legal Matters The Company is frequently made party to a variety of legal actions and regulatory inquiries, including class actions and suits brought by members, care providers, consumer advocacy organizations, customers and regulators, relating to the Company’s businesses, including management and administration of health benefit plans and other services. These matters include medical malpractice, employment, intellectual property, antitrust, privacy and contract claims and claims related to health care benefits coverage and other business practices. The Company records liabilities for its estimates of probable costs resulting from these matters where appropriate. Estimates of costs resulting from legal and regulatory matters involving the Company are inherently difficult to predict, particularly where the matters: involve indeterminate claims for monetary damages or may involve fines, penalties or punitive damages; present novel legal theories or represent a shift in regulatory policy; involve a large number of claimants or regulatory bodies; are in the early stages of the proceedings; or could result in a change in business practices. Accordingly, the Company is often unable to estimate the losses or ranges of losses for those matters where there is a reasonable possibility or it is probable a loss may be incurred. Government Investigations, Audits and Reviews The Company has been involved or is currently involved in various governmental investigations, audits and reviews. These include routine, regular and special investigations, audits and reviews by the Centers for Medicare and Medicaid Services (CMS), state insurance and health and welfare departments, state attorneys general, the Office of the Inspector General, the Office of Personnel Management, the Office of Civil Rights, the Government Accountability Office, the Federal Trade Commission, U.S. Congressional committees, the U.S. Department of Justice (DOJ), the SEC, the Internal Revenue Service, the U.S. Drug Enforcement Administration, the U.S. Department of Labor, the Federal Deposit Insurance Corporation, the Consumer Financial Protection Bureau (CFPB), the Defense Contract Audit Agency and other governmental authorities. Similarly, our international businesses are also subject to investigations, audits and reviews by applicable foreign governments, including South American and other non-U.S. governmental authorities. Certain of the Company’s businesses have been reviewed or are currently under review, including for, among other matters, compliance with coding and other requirements under the Medicare risk-adjustment model. CMS has selected certain of the Company’s local plans for risk adjustment data validation (RADV) audits to validate the coding practices of and supporting documentation maintained by health care providers and such audits may result in retrospective adjustments to payments made to the Company’s health plans. On February 14, 2017, the DOJ announced its decision to pursue certain claims within a lawsuit initially asserted against the Company and filed under seal by a whistleblower in 2011. The whistleblower’s complaint, which was unsealed on February 15, 2017, alleges the Company made improper risk adjustment submissions and violated the False Claims Act. On February 12, 2018, the court granted in part and denied in part the Company’s motion to dismiss. In May 2018, the DOJ moved to dismiss the Company’s counterclaims, which were filed in March 2018, and moved for partial summary judgment. In March 2019, the court denied the government’s motion for partial summary judgment and dismissed the Company’s counterclaims without prejudice. The Company cannot reasonably estimate the outcome which may result from this matter given its procedural status.

Business Combinations (Notes)

Business Combinations (Notes)	3 Months Ended
	Mar. 31, 2023
Business Combination and Asset Acquisition [Abstract]
Business Combination Disclosure	Business Combinations During the three months ended March 31, 2023, the Company completed several business combinations for total consideration of $8.0 billion. Acquired assets (liabilities) at acquisition date were: (in millions) Cash and cash equivalents $ 142 Accounts receivable and other current assets 530 Property, equipment and other long-term assets 659 Other intangible assets 2,141 Total identifiable assets acquired 3,472 Medical costs payable (1) Accounts payable and other current liabilities (467) Other long-term liabilities (698) Total identifiable liabilities acquired (1,166) Total net identifiable assets 2,306 Goodwill 6,646 Redeemable noncontrolling interests (130) Nonredeemable noncontrolling interests (819) Net assets acquired $ 8,003 The majority of goodwill is not deductible for income tax purposes. The preliminary purchase price allocations for the various business combinations are subject to adjustment as valuation analyses, primarily related to intangible assets and contingent liabilities, are finalized. The acquisition date fair values and weighted-average useful lives assigned to intangible assets were: (in millions, except years) Fair Value Weighted-Average Useful Life Acquired finite-lived intangible assets: Customer-related $ 234 13 years Trademarks and technology 220 5 years Other 10 11 years Total acquired finite-lived intangible assets 464 9 years Total acquired indefinite-lived intangible assets - operating licenses and certificates 1,677 Total acquired intangible assets $ 2,141 The results of operations and financial condition of acquired entities have been included in the Company’s consolidated results and the results of the corresponding operating segment as of the date of acquisition. Through March 31, 2023, acquired entities impact on revenues and net earnings was not material. Unaudited pro forma revenues and net earnings for the three months ended March 31, 2023 and 2022, as if the business combinations had occurred on January 1, 2022, were immaterial for both periods.

Segment Financial Information (

Segment Financial Information (Notes)	3 Months Ended
	Mar. 31, 2023
Segment Reporting [Abstract]
Segment Reporting Disclosure	Segment Financial Information The Company’s four reportable segments are UnitedHealthcare, Optum Health, Optum Insight and Optum Rx. For more information on the Company’s segments, see Part I, Item I, “Business” and Note 14 of Notes to the Consolidated Financial Statements included in Part II, Item 8, “Financial Statements and Supplementary Data” in the 2022 10-K. Total assets at Optum Health increased to $80.4 billion as of March 31, 2023 compared to $69.0 billion as of December 31, 2022, primarily due to goodwill from business combinations of $5.9 billion. The following tables present reportable segment financial information: Optum (in millions) UnitedHealthcare Optum Health Optum Insight Optum Rx Optum Eliminations Optum Corporate and Consolidated Three Months Ended March 31, 2023 Revenues - unaffiliated customers: Premiums $ 67,458 $ 5,328 $ — $ — $ — $ 5,328 $ — $ 72,786 Products — 44 40 10,183 — 10,267 — 10,267 Services 2,555 3,089 1,926 510 — 5,525 — 8,080 Total revenues - unaffiliated customers 70,013 8,461 1,966 10,693 — 21,120 — 91,133 Total revenues - affiliated customers — 14,266 2,510 16,679 (859) 32,596 (32,596) — Investment and other income 455 277 20 46 — 343 — 798 Total revenues $ 70,468 $ 23,004 $ 4,496 $ 27,418 $ (859) $ 54,059 $ (32,596) $ 91,931 Earnings from operations $ 4,343 $ 1,776 $ 907 $ 1,060 $ — $ 3,743 $ — $ 8,086 Interest expense — — — — — — (754) (754) Earnings before income taxes $ 4,343 $ 1,776 $ 907 $ 1,060 $ — $ 3,743 $ (754) $ 7,332 Three Months Ended March 31, 2022 Revenues - unaffiliated customers: Premiums $ 59,937 $ 4,133 $ — $ — $ — $ 4,133 $ — $ 64,070 Products — 6 40 9,294 — 9,340 — 9,340 Services 2,515 2,558 974 325 — 3,857 — 6,372 Total revenues - unaffiliated customers 62,452 6,697 1,014 9,619 — 17,330 — 79,782 Total revenues - affiliated customers — 9,829 2,138 14,291 (553) 25,705 (25,705) — Investment and other income 143 156 67 1 — 224 — 367 Total revenues $ 62,595 $ 16,682 $ 3,219 $ 23,911 $ (553) $ 43,259 $ (25,705) $ 80,149 Earnings from operations $ 3,798 $ 1,366 $ 847 $ 939 $ — $ 3,152 $ — $ 6,950 Interest expense — — — — — — (433) (433) Earnings before income taxes $ 3,798 $ 1,366 $ 847 $ 939 $ — $ 3,152 $ (433) $ 6,517

Basis of Presentation (Policies

Basis of Presentation (Policies)	3 Months Ended
	Mar. 31, 2023
Basis of presentation [Abstract]
Basis of Accounting, Policy [Policy Text Block]	The Company has prepared the Condensed Consolidated Financial Statements according to U.S. Generally Accepted Accounting Principles (GAAP) and has included the accounts of UnitedHealth Group and its subsidiaries. The year-end condensed consolidated balance sheet was derived from audited financial statements, but does not include all disclosures required by GAAP. In accordance with the rules and regulations of the U.S. Securities and Exchange Commission (SEC), the Company has omitted certain footnote disclosures that would substantially duplicate the disclosures contained in its annual audited Consolidated Financial Statements. Therefore, these Condensed Consolidated Financial Statements should be read together with the Consolidated Financial Statements and the Notes included in Part II, Item 8, “Financial Statements and Supplementary Data” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022 as filed with the SEC (2022 10-K). The accompanying Condensed Consolidated Financial Statements include all normal recurring adjustments necessary to present the interim financial statements fairly.
Use of Estimates, Policy [Policy Text Block]	These Condensed Consolidated Financial Statements include certain amounts based on the Company’s best estimates and judgments. The Company’s most significant estimates relate to estimates and judgments for medical costs payable and goodwill. Certain of these estimates require the application of complex assumptions and judgments, often because they involve matters that are inherently uncertain and will likely change in subsequent periods. The impact of any change in estimates is included in earnings in the period in which the estimate is adjusted.
Revenue [Policy Text Block]	As of March 31, 2023 and December 31, 2022, accounts receivable related to products and services were $8.1 billion and $7.1 billion, respectively. Revenue expected to be recognized in any future year related to remaining performance obligations, excluding revenue pertaining to contracting having an original expected duration of one year or less, contracts where revenue recognized as invoiced and contracts with variable consideration related undelivered performance obligations, was $12.3 billion, of which approximately half is expected to be recognized in the next three years.

Investments (Policies)

Investments (Policies)	3 Months Ended
	Mar. 31, 2023
Investments [Abstract]
Investment, Policy [Policy Text Block]	At each reporting period, the Company evaluates available-for-sale debt securities for any credit-related impairment when the fair value of the investment is less than its amortized cost. The Company evaluated the expected cash flows, the underlying credit quality and credit ratings of the issuers noting no significant credit deterioration since purchase. As of March 31, 2023, the Company did not have the intent to sell any of the available-for-sale debt securities in an unrealized loss position. Therefore, the Company believes these losses to be temporary.

Investments (Tables)

Investments (Tables)	3 Months Ended
	Mar. 31, 2023
Short-Term and Long-Term Investments [Table Text Block]	A summary of debt securities by major security type is as follows: (in millions) Amortized Gross Gross Fair March 31, 2023 Debt securities - available-for-sale: U.S. government and agency obligations $ 4,760 $ 5 $ (236) $ 4,529 State and municipal obligations 8,055 65 (365) 7,755 Corporate obligations 24,149 59 (1,525) 22,683 U.S. agency mortgage-backed securities 8,213 35 (708) 7,540 Non-U.S. agency mortgage-backed securities 3,156 1 (283) 2,874 Total debt securities - available-for-sale 48,333 165 (3,117) 45,381 Debt securities - held-to-maturity: U.S. government and agency obligations 594 — (10) 584 State and municipal obligations 28 — (3) 25 Corporate obligations 60 — — 60 Total debt securities - held-to-maturity 682 — (13) 669 Total debt securities $ 49,015 $ 165 $ (3,130) $ 46,050 December 31, 2022 Debt securities - available-for-sale: U.S. government and agency obligations $ 4,093 $ 1 $ (285) $ 3,809 State and municipal obligations 7,702 25 (479) 7,248 Corporate obligations 23,675 17 (1,798) 21,894 U.S. agency mortgage-backed securities 7,379 15 (808) 6,586 Non-U.S. agency mortgage-backed securities 3,077 1 (294) 2,784 Total debt securities - available-for-sale 45,926 59 (3,664) 42,321 Debt securities - held-to-maturity: U.S. government and agency obligations 578 — (14) 564 State and municipal obligations 29 — (3) 26 Corporate obligations 89 — — 89 Total debt securities - held-to-maturity 696 — (17) 679 Total debt securities $ 46,622 $ 59 $ (3,681) $ 43,000
Investments by Contractual Maturity [Table Text Block]	The amortized cost and fair value of debt securities as of March 31, 2023, by contractual maturity, were as follows: Available-for-Sale Held-to-Maturity (in millions) Amortized Fair Amortized Fair Due in one year or less $ 4,722 $ 4,691 $ 377 $ 376 Due after one year through five years 14,356 13,708 261 254 Due after five years through ten years 12,240 11,217 24 22 Due after ten years 5,646 5,351 20 17 U.S. agency mortgage-backed securities 8,213 7,540 — — Non-U.S. agency mortgage-backed securities 3,156 2,874 — — Total debt securities $ 48,333 $ 45,381 $ 682 $ 669
Debt Securities, Available-for-sale, Unrealized Loss Position, Fair Value	The fair value of available-for-sale debt securities with gross unrealized losses by major security type and length of time that individual securities have been in a continuous unrealized loss position were as follows: Less Than 12 Months 12 Months or Greater Total (in millions) Fair Gross Fair Gross Fair Gross March 31, 2023 Debt securities - available-for-sale: U.S. government and agency obligations $ 1,279 $ (12) $ 1,825 $ (224) $ 3,104 $ (236) State and municipal obligations 1,898 (30) 3,110 (335) 5,008 (365) Corporate obligations 6,337 (178) 12,443 (1,347) 18,780 (1,525) U.S. agency mortgage-backed securities 1,589 (55) 4,274 (653) 5,863 (708) Non-U.S. agency mortgage-backed securities 783 (26) 1,989 (257) 2,772 (283) Total debt securities - available-for-sale $ 11,886 $ (301) $ 23,641 $ (2,816) $ 35,527 $ (3,117) December 31, 2022 Debt securities - available-for-sale: U.S. government and agency obligations $ 2,007 $ (96) $ 1,290 $ (189) $ 3,297 $ (285) State and municipal obligations 4,630 (288) 1,178 (191) 5,808 (479) Corporate obligations 13,003 (893) 6,637 (905) 19,640 (1,798) U.S. agency mortgage-backed securities 3,561 (345) 2,239 (463) 5,800 (808) Non-U.S. agency mortgage-backed securities 1,698 (128) 976 (166) 2,674 (294) Total debt securities - available-for-sale $ 24,899 $ (1,750) $ 12,320 $ (1,914) $ 37,219 $ (3,664)

Fair Value (Tables)

Fair Value (Tables)	3 Months Ended
	Mar. 31, 2023
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial Assets and Liabilities, Measured at Fair Value Recurring Basis [Table Text Block]	The following table presents a summary of fair value measurements by level and carrying values for items measured at fair value on a recurring basis in the Condensed Consolidated Balance Sheets: (in millions) Quoted Prices Other Unobservable Total March 31, 2023 Cash and cash equivalents $ 41,851 $ 62 $ — $ 41,913 Debt securities - available-for-sale: U.S. government and agency obligations 4,122 407 — 4,529 State and municipal obligations — 7,755 — 7,755 Corporate obligations 16 22,486 181 22,683 U.S. agency mortgage-backed securities — 7,540 — 7,540 Non-U.S. agency mortgage-backed securities — 2,874 — 2,874 Total debt securities - available-for-sale 4,138 41,062 181 45,381 Equity securities 2,128 35 70 2,233 Assets under management 1,491 2,245 101 3,837 Total assets at fair value $ 49,608 $ 43,404 $ 352 $ 93,364 Percentage of total assets at fair value 53 % 46 % 1 % 100 % December 31, 2022 Cash and cash equivalents $ 23,202 $ 163 $ — $ 23,365 Debt securities - available-for-sale: U.S. government and agency obligations 3,505 304 — 3,809 State and municipal obligations — 7,248 — 7,248 Corporate obligations 7 21,695 192 21,894 U.S. agency mortgage-backed securities — 6,586 — 6,586 Non-U.S. agency mortgage-backed securities — 2,784 — 2,784 Total debt securities - available-for-sale 3,512 38,617 192 42,321 Equity securities 2,043 35 70 2,148 Assets under management 1,788 2,203 96 4,087 Total assets at fair value $ 30,545 $ 41,018 $ 358 $ 71,921 Percentage of total assets at fair value 42 % 57 % 1 % 100 %
Fair Value Measurements, Nonrecurring [Table Text Block]	The following table presents a summary of fair value measurements by level and carrying values for certain financial instruments not measured at fair value on a recurring basis in the Condensed Consolidated Balance Sheets: (in millions) Quoted Prices Other Unobservable Total Total Carrying Value March 31, 2023 Debt securities - held-to-maturity $ 595 $ 74 $ — $ 669 $ 682 Long-term debt and other financing obligations $ — $ 60,307 $ — $ 60,307 $ 62,360 December 31, 2022 Debt securities - held-to-maturity $ 577 $ 102 $ — $ 679 $ 696 Long-term debt and other financing obligations $ — $ 53,626 $ — $ 53,626 $ 56,823

Medical Costs Payable (Tables)

Medical Costs Payable (Tables)	3 Months Ended
	Mar. 31, 2023
Insurance [Abstract]
Schedule of Liability for Unpaid Claims and Claims Adjustment Expense	The following table shows the components of the change in medical costs payable for the three months ended March 31: (in millions) 2023 2022 Medical costs payable, beginning of period $ 29,056 $ 24,483 Acquisitions 1 8 Reported medical costs: Current year 60,315 52,813 Prior years (470) (290) Total reported medical costs 59,845 52,523 Medical payments: Payments for current year (35,087) (29,589) Payments for prior years (22,006) (18,749) Total medical payments (57,093) (48,338) Medical costs payable, end of period $ 31,809 $ 28,676

Short-Term Borrowings and Lon_2

Short-Term Borrowings and Long-Term Debt (Tables)	3 Months Ended
	Mar. 31, 2023
Debt Instrument [Line Items]
Long-Term Debt [Table Text Block]	In March 2023, the Company issued $6.5 billion of senior unsecured notes consisting of the following: (in millions, except percentages) Par Value 4.250% notes due January 2029 $ 1,250 4.500% notes due April 2033 1,500 5.050% notes due April 2053 2,000 5.200% notes due April 2063 1,750

Business Combinations (Tables)

Business Combinations (Tables)	3 Months Ended
	Mar. 31, 2023
Business Combination and Asset Acquisition [Abstract]
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]	Acquired assets (liabilities) at acquisition date were: (in millions) Cash and cash equivalents $ 142 Accounts receivable and other current assets 530 Property, equipment and other long-term assets 659 Other intangible assets 2,141 Total identifiable assets acquired 3,472 Medical costs payable (1) Accounts payable and other current liabilities (467) Other long-term liabilities (698) Total identifiable liabilities acquired (1,166) Total net identifiable assets 2,306 Goodwill 6,646 Redeemable noncontrolling interests (130) Nonredeemable noncontrolling interests (819) Net assets acquired $ 8,003
Finite-Lived and Indefinite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block]	The acquisition date fair values and weighted-average useful lives assigned to intangible assets were: (in millions, except years) Fair Value Weighted-Average Useful Life Acquired finite-lived intangible assets: Customer-related $ 234 13 years Trademarks and technology 220 5 years Other 10 11 years Total acquired finite-lived intangible assets 464 9 years Total acquired indefinite-lived intangible assets - operating licenses and certificates 1,677 Total acquired intangible assets $ 2,141

Segment Financial Information_2

Segment Financial Information (Tables)	3 Months Ended
	Mar. 31, 2023
Segment Reporting [Abstract]
Schedule of Segment Reporting Information, by Segment	The following tables present reportable segment financial information: Optum (in millions) UnitedHealthcare Optum Health Optum Insight Optum Rx Optum Eliminations Optum Corporate and Consolidated Three Months Ended March 31, 2023 Revenues - unaffiliated customers: Premiums $ 67,458 $ 5,328 $ — $ — $ — $ 5,328 $ — $ 72,786 Products — 44 40 10,183 — 10,267 — 10,267 Services 2,555 3,089 1,926 510 — 5,525 — 8,080 Total revenues - unaffiliated customers 70,013 8,461 1,966 10,693 — 21,120 — 91,133 Total revenues - affiliated customers — 14,266 2,510 16,679 (859) 32,596 (32,596) — Investment and other income 455 277 20 46 — 343 — 798 Total revenues $ 70,468 $ 23,004 $ 4,496 $ 27,418 $ (859) $ 54,059 $ (32,596) $ 91,931 Earnings from operations $ 4,343 $ 1,776 $ 907 $ 1,060 $ — $ 3,743 $ — $ 8,086 Interest expense — — — — — — (754) (754) Earnings before income taxes $ 4,343 $ 1,776 $ 907 $ 1,060 $ — $ 3,743 $ (754) $ 7,332 Three Months Ended March 31, 2022 Revenues - unaffiliated customers: Premiums $ 59,937 $ 4,133 $ — $ — $ — $ 4,133 $ — $ 64,070 Products — 6 40 9,294 — 9,340 — 9,340 Services 2,515 2,558 974 325 — 3,857 — 6,372 Total revenues - unaffiliated customers 62,452 6,697 1,014 9,619 — 17,330 — 79,782 Total revenues - affiliated customers — 9,829 2,138 14,291 (553) 25,705 (25,705) — Investment and other income 143 156 67 1 — 224 — 367 Total revenues $ 62,595 $ 16,682 $ 3,219 $ 23,911 $ (553) $ 43,259 $ (25,705) $ 80,149 Earnings from operations $ 3,798 $ 1,366 $ 847 $ 939 $ — $ 3,152 $ — $ 6,950 Interest expense — — — — — — (433) (433) Earnings before income taxes $ 3,798 $ 1,366 $ 847 $ 939 $ — $ 3,152 $ (433) $ 6,517

Basis of Presentation (Details)

Basis of Presentation (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Nature of Operations	UnitedHealth Group Incorporated (individually and together with its subsidiaries, “UnitedHealth Group” and the “Company”) is a health care and well-being company with a mission to help people live healthier lives and help make the health system work better for everyone. Our two distinct, yet complementary business platforms — Optum and UnitedHealthcare — are working to help build a modern, high-performing health system through improved access, affordability, outcomes and experiences for the individuals and organizations the Company is privileged to serve.
Accounts Receivable, after Allowance for Credit Loss, Current	$ 22,414	$ 17,681
Revenue, Remaining Performance Obligation, Amount	$ 12,300
Revenue, Remaining Performance Obligation, Percentage	50%
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-04-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period	3 years
unh:ProductsandservicesMember
Accounts Receivable, after Allowance for Credit Loss, Current	$ 8,100	$ 7,100

Investments (Narrative) (Detail

Investments (Narrative) (Details) $ in Millions	Mar. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)
Investments [Abstract]
Equity Securities, FV-NI and without Readily Determinable Fair Value	$ 3,900	$ 3,700
Equity Method Investments	$ 1,500
Debt Securities, Available-for-sale, Unrealized Loss Position, Number of Positions	32,000
Total number of security positions	42,000

Investments (Short-Term and Lon

Investments (Short-Term and Long-Term Investments) (Details) - USD ($) $ in Millions	Mar. 31, 2023	Dec. 31, 2022
Schedule of Investments [Line Items]
Debt Securities, Available-for-sale, Amortized Cost	$ 48,333	$ 45,926
Securities, Available for sale Debt Securities, Gross Unrealized Gains	165	59
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax	(3,117)	(3,664)
Debt Securities, Available-for-sale	45,381	42,321
Held-to-maturity securities, Amortized Cost	682	696
Securities, Held to maturity, Unrecognized Holding Gain	0	0
Debt Securities, Held-to-maturity, Accumulated Unrecognized Loss	(13)	(17)
Debt Securities, Held-to-maturity, Fair Value	669	679
Total debt securities, Amortized Cost	49,015	46,622
Total debt securities, Gross Unrealized Gains	165	59
Total debt securities, Gross Unrealized Losses	(3,130)	(3,681)
Debt securities, Fair Value Disclosure	46,050	43,000
Debt Securities [Member]
Schedule of Investments [Line Items]
Debt Securities, Available-for-sale	45,381	42,321
U.S. Government and Agency Obligations [Member]
Schedule of Investments [Line Items]
Debt Securities, Available-for-sale, Amortized Cost	4,760	4,093
Securities, Available for sale Debt Securities, Gross Unrealized Gains	5	1
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax	(236)	(285)
Debt Securities, Available-for-sale	4,529	3,809
Held-to-maturity securities, Amortized Cost	594	578
Securities, Held to maturity, Unrecognized Holding Gain	0	0
Debt Securities, Held-to-maturity, Accumulated Unrecognized Loss	(10)	(14)
Debt Securities, Held-to-maturity, Fair Value	584	564
State and Municipal Obligations [Member]
Schedule of Investments [Line Items]
Debt Securities, Available-for-sale, Amortized Cost	8,055	7,702
Securities, Available for sale Debt Securities, Gross Unrealized Gains	65	25
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax	(365)	(479)
Debt Securities, Available-for-sale	7,755	7,248
Held-to-maturity securities, Amortized Cost	28	29
Securities, Held to maturity, Unrecognized Holding Gain	0	0
Debt Securities, Held-to-maturity, Accumulated Unrecognized Loss	(3)	(3)
Debt Securities, Held-to-maturity, Fair Value	25	26
Corporate Obligations [Member]
Schedule of Investments [Line Items]
Debt Securities, Available-for-sale, Amortized Cost	24,149	23,675
Securities, Available for sale Debt Securities, Gross Unrealized Gains	59	17
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax	(1,525)	(1,798)
Debt Securities, Available-for-sale	22,683	21,894
Held-to-maturity securities, Amortized Cost	60	89
Securities, Held to maturity, Unrecognized Holding Gain	0	0
Debt Securities, Held-to-maturity, Accumulated Unrecognized Loss	0	0
Debt Securities, Held-to-maturity, Fair Value	60	89
U.S. Agency Mortgage-Backed Securities [Member]
Schedule of Investments [Line Items]
Debt Securities, Available-for-sale, Amortized Cost	8,213	7,379
Securities, Available for sale Debt Securities, Gross Unrealized Gains	35	15
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax	(708)	(808)
Debt Securities, Available-for-sale	7,540	6,586
Non-U.S. Agency Mortgage-Backed Securities [Member]
Schedule of Investments [Line Items]
Debt Securities, Available-for-sale, Amortized Cost	3,156	3,077
Securities, Available for sale Debt Securities, Gross Unrealized Gains	1	1
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax	(283)	(294)
Debt Securities, Available-for-sale	$ 2,874	$ 2,784

Investments (Amortized Cost and

Investments (Amortized Cost and Fair Value of Available-for-Sale Debt Securities by Contractual Maturity) (Details) - USD ($) $ in Millions	Mar. 31, 2023	Dec. 31, 2022
Schedule of Investments [Line Items]
Due in one year or less, Amortized Cost	$ 4,722
Due after one year through five years, Amortized Cost	14,356
Due after five years through ten years, Amortized Cost	12,240
Due after ten years, Amortized Cost	5,646
Total debt securities - available-for-sale, Amortized Cost	48,333	$ 45,926
Due in one year or less, Fair Value	4,691
Due after one year through five years, Fair Value	13,708
Due after five years through ten years, Fair Value	11,217
Due after ten years, Fair Value	5,351
Debt Securities, Available-for-sale	45,381	42,321
Debt Securities, Held-to-Maturity, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One	377
Debt Securities, Held-to-Maturity, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five	261
Debt Securities, Held-to-Maturity, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10	24
Debt Securities, Held-to-Maturity, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year 10	20
Debt Securities, Held-to-maturity	682	696
Held-to-maturity Securities, Debt Maturities, within One Year, Fair Value	376
Debt Securities, Held-to-Maturity, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five	254
Debt Securities, Held-to-Maturity, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10	22
Debt Securities, Held-to-Maturity, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 10	17
Debt Securities, Held-to-maturity, Fair Value	669	679
U.S. Agency Mortgage-Backed Securities [Member]
Schedule of Investments [Line Items]
Mortgage-backed securities, Amortized Cost	8,213
Total debt securities - available-for-sale, Amortized Cost	8,213	7,379
Mortgage-backed securities, Fair Value	7,540
Debt Securities, Available-for-sale	7,540	6,586
Non-U.S. Agency Mortgage-Backed Securities [Member]
Schedule of Investments [Line Items]
Mortgage-backed securities, Amortized Cost	3,156
Total debt securities - available-for-sale, Amortized Cost	3,156	3,077
Mortgage-backed securities, Fair Value	2,874
Debt Securities, Available-for-sale	$ 2,874	$ 2,784

Investments (Fair Value of Avai

Investments (Fair Value of Available-For-Sale Investments with Gross Unrealized Losses by Investment Type and Length of Time That Individual Securities Have Been in a Continuous Unrealized Loss Position) (Details) - USD ($) $ in Millions	Mar. 31, 2023	Dec. 31, 2022
Debt Securities [Member]
Schedule of Investments [Line Items]
Less Than 12 Months, Fair Value	$ 11,886	$ 24,899
Less Than 12 Months, Gross Unrealized Losses	(301)	(1,750)
Greater Than 12 Months, Fair Value	23,641	12,320
Greater Than 12 Months, Gross Unrealized Losses	(2,816)	(1,914)
Total, Fair Value	35,527	37,219
Available-for-sale Securities, Continuous Unrealized Loss Position, Accumulated Loss	(3,117)	(3,664)
U.S. Government and Agency Obligations [Member]
Schedule of Investments [Line Items]
Less Than 12 Months, Fair Value	1,279	2,007
Less Than 12 Months, Gross Unrealized Losses	(12)	(96)
Greater Than 12 Months, Fair Value	1,825	1,290
Greater Than 12 Months, Gross Unrealized Losses	(224)	(189)
Total, Fair Value	3,104	3,297
Available-for-sale Securities, Continuous Unrealized Loss Position, Accumulated Loss	(236)	(285)
State and Municipal Obligations [Member]
Schedule of Investments [Line Items]
Less Than 12 Months, Fair Value	1,898	4,630
Less Than 12 Months, Gross Unrealized Losses	(30)	(288)
Greater Than 12 Months, Fair Value	3,110	1,178
Greater Than 12 Months, Gross Unrealized Losses	(335)	(191)
Total, Fair Value	5,008	5,808
Available-for-sale Securities, Continuous Unrealized Loss Position, Accumulated Loss	(365)	(479)
Corporate Obligations [Member]
Schedule of Investments [Line Items]
Less Than 12 Months, Fair Value	6,337	13,003
Less Than 12 Months, Gross Unrealized Losses	(178)	(893)
Greater Than 12 Months, Fair Value	12,443	6,637
Greater Than 12 Months, Gross Unrealized Losses	(1,347)	(905)
Total, Fair Value	18,780	19,640
Available-for-sale Securities, Continuous Unrealized Loss Position, Accumulated Loss	(1,525)	(1,798)
U.S. Agency Mortgage-Backed Securities [Member]
Schedule of Investments [Line Items]
Less Than 12 Months, Fair Value	1,589	3,561
Less Than 12 Months, Gross Unrealized Losses	(55)	(345)
Greater Than 12 Months, Fair Value	4,274	2,239
Greater Than 12 Months, Gross Unrealized Losses	(653)	(463)
Total, Fair Value	5,863	5,800
Available-for-sale Securities, Continuous Unrealized Loss Position, Accumulated Loss	(708)	(808)
Non-U.S. Agency Mortgage-Backed Securities [Member]
Schedule of Investments [Line Items]
Less Than 12 Months, Fair Value	783	1,698
Less Than 12 Months, Gross Unrealized Losses	(26)	(128)
Greater Than 12 Months, Fair Value	1,989	976
Greater Than 12 Months, Gross Unrealized Losses	(257)	(166)
Total, Fair Value	2,772	2,674
Available-for-sale Securities, Continuous Unrealized Loss Position, Accumulated Loss	$ (283)	$ (294)

Fair Value (Narrative) (Details

Fair Value (Narrative) (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Fair Value [Line Items]
Transfers Into Level 3	$ 0	$ 0
Transfers out of Level 3	0	0
Significant fair value adjustments for assets and liabilities measured on a nonrecurring basis	$ 0	$ 0

Fair Value (Financial Assets an

Fair Value (Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis) (Details) - USD ($) $ in Millions	Mar. 31, 2023	Dec. 31, 2022
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	$ 41,913	$ 23,365
Debt Securities, Available-for-sale	45,381	42,321
Equity Securities, FV-NI	2,233	2,148
Assets under management	3,837	4,087
Assets, Fair Value Disclosure	93,364	71,921
Debt Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	45,381	42,321
U.S. Government and Agency Obligations [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	4,529	3,809
State and Municipal Obligations [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	7,755	7,248
Corporate Obligations [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	22,683	21,894
U.S. Agency Mortgage-Backed Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	7,540	6,586
Non-U.S. Agency Mortgage-Backed Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	2,874	2,784
Quoted Prices in Active Markets (Level 1) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	41,851	23,202
Equity Securities, FV-NI	2,128	2,043
Assets under management	1,491	1,788
Assets, Fair Value Disclosure	49,608	30,545
Quoted Prices in Active Markets (Level 1) [Member] | Debt Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	4,138	3,512
Quoted Prices in Active Markets (Level 1) [Member] | U.S. Government and Agency Obligations [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	4,122	3,505
Quoted Prices in Active Markets (Level 1) [Member] | State and Municipal Obligations [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	0	0
Quoted Prices in Active Markets (Level 1) [Member] | Corporate Obligations [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	16	7
Quoted Prices in Active Markets (Level 1) [Member] | U.S. Agency Mortgage-Backed Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	0	0
Quoted Prices in Active Markets (Level 1) [Member] | Non-U.S. Agency Mortgage-Backed Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	0	0
Other Observable Inputs (Level 2) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	62	163
Equity Securities, FV-NI	35	35
Assets under management	2,245	2,203
Assets, Fair Value Disclosure	43,404	41,018
Other Observable Inputs (Level 2) [Member] | Debt Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	41,062	38,617
Other Observable Inputs (Level 2) [Member] | U.S. Government and Agency Obligations [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	407	304
Other Observable Inputs (Level 2) [Member] | State and Municipal Obligations [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	7,755	7,248
Other Observable Inputs (Level 2) [Member] | Corporate Obligations [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	22,486	21,695
Other Observable Inputs (Level 2) [Member] | U.S. Agency Mortgage-Backed Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	7,540	6,586
Other Observable Inputs (Level 2) [Member] | Non-U.S. Agency Mortgage-Backed Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	2,874	2,784
Unobservable Inputs (Level 3) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	0	0
Equity Securities, FV-NI	70	70
Assets under management	101	96
Assets, Fair Value Disclosure	352	358
Unobservable Inputs (Level 3) [Member] | Debt Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	181	192
Unobservable Inputs (Level 3) [Member] | U.S. Government and Agency Obligations [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	0	0
Unobservable Inputs (Level 3) [Member] | State and Municipal Obligations [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	0	0
Unobservable Inputs (Level 3) [Member] | Corporate Obligations [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	181	192
Unobservable Inputs (Level 3) [Member] | U.S. Agency Mortgage-Backed Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	0	0
Unobservable Inputs (Level 3) [Member] | Non-U.S. Agency Mortgage-Backed Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	$ 0	$ 0

Fair Value (Financial Assets _2

Fair Value (Financial Assets and Liabilities, Not Measured at Fair Value on a Recurring Basis) (Details) - USD ($) $ in Millions	Mar. 31, 2023	Dec. 31, 2022
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Held-to-maturity, Fair Value	$ 669	$ 679
Debt Securities, Held-to-maturity	682	696
Fair Value, Nonrecurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Held-to-maturity, Fair Value	669	679
Debt and other financing obligations	60,307	53,626
Fair Value, Nonrecurring [Member] | Quoted Prices in Active Markets (Level 1) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Held-to-maturity, Fair Value	595	577
Debt and other financing obligations	0	0
Fair Value, Nonrecurring [Member] | Other Observable Inputs (Level 2) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Held-to-maturity, Fair Value	74	102
Debt and other financing obligations	60,307	53,626
Fair Value, Nonrecurring [Member] | Unobservable Inputs (Level 3) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Held-to-maturity, Fair Value	0	0
Debt and other financing obligations	0	0
Long-term debt and other financing obligations
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt and other financing obligations, carrying value	$ 62,360	$ 56,823

Medical Costs Payable (Narrativ

Medical Costs Payable (Narrative) (Details) - USD ($) $ in Billions	Mar. 31, 2023	Dec. 31, 2022
Insurance [Abstract]
Liability for Unpaid Claims and Claims Adjustment Expense, Incurred but Not Reported (IBNR) Claims, Amount	$ 21.7	$ 20

Medical Costs Payable (Details)

Medical Costs Payable (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Causes of Increase (Decrease) in Liability for Unpaid Claims and Claims Adjustment Expense [Line Items]
Medical costs payable, beginning of period	$ 29,056	$ 24,483
Acquisitions	1	8
Reported medical costs:
Current year	60,315	52,813
Prior year	(470)	(290)
Total reported medical costs	59,845	52,523
Medical payments:
Payments for current year	(35,087)	(29,589)
Payments for prior years	(22,006)	(18,749)
Total medical payments	(57,093)	(48,338)
Medical costs payable, end of period	$ 31,809	$ 28,676

Short-Term Borrowings and Lon_3

Short-Term Borrowings and Long-Term Debt (Details) $ in Millions	Mar. 31, 2023 USD ($)
Debt Instrument [Line Items]
Par Value	$ 6,500
Commercial Paper	$ 8,200
4.250% notes due January 2029
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	4.25%
Par Value	$ 1,250
4.500% notes due April 2033
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	4.50%
Par Value	$ 1,500
5.050% notes due April 2053
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	5.05%
Par Value	$ 2,000
5.200% notes due April 2063
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	5.20%
Par Value	$ 1,750

Short-Term Borrowings and Lon_4

Short-Term Borrowings and Long-Term Debt (Narrative) (Details) $ in Millions	Mar. 31, 2023 USD ($) Rate
Debt Instrument [Line Items]
Commercial Paper | $	$ 8,200
Commercial Paper [Member]
Debt Instrument [Line Items]
Short-term Debt, Weighted Average Interest Rate, at Point in Time | Rate	5.20%

Business Combinations (Narrativ

Business Combinations (Narrative) (Details) $ in Millions	3 Months Ended
	Mar. 31, 2023 USD ($)
Business Combination and Asset Acquisition [Abstract]
Business Combination, Consideration Transferred	$ 8,000

Business Combinations (Details)

Business Combinations (Details) $ in Millions	3 Months Ended
	Mar. 31, 2023 USD ($)
Business Acquisition [Line Items]
Cash and cash equivalents	$ 142
Accounts receivable and other current assets	530
Property, equipment and other long-term assets	659
Other Intangible Assets	2,141
Total identifiable assets acquired	3,472
Medical costs payable	(1)
Accounts payable and other current liabilities	(467)
Other long-term liabilities	(698)
Total identifiable liabilities acquired	(1,166)
Total net tangible assets	2,306
Goodwill	6,646
Redeemable noncontrolling interests	(130)
Nonredeemable noncontrolling interests	(819)
Net Assets Acquired	$ 8,003

Business Combinations Acquired

Business Combinations Acquired Finite-Lived Intangible Asets (Details) $ in Millions	3 Months Ended
	Mar. 31, 2023 USD ($)
Finite-Lived Intangible Assets [Line Items]
Finite-lived Intangible Assets Acquired	$ 464
Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life	9 years
Indefinite-Lived Intangible Assets Acquired	$ 1,677
Other Intangible Assets	2,141
Customer-Related Intangible Assets [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-lived Intangible Assets Acquired	$ 234
Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life	13 years
Trademarks and Technology [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-lived Intangible Assets Acquired	$ 220
Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life	5 years
Other Intangible Assets [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-lived Intangible Assets Acquired	$ 10
Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life	11 years

Segment Financial Information_3

Segment Financial Information (Narrative) (Details) $ in Millions	3 Months Ended
	Mar. 31, 2023 USD ($) reportableSegments	Dec. 31, 2022 USD ($)
Statement [Line Items]
Number of Reportable Segments | reportableSegments	4
Assets	$ 283,679	$ 245,705
Goodwill	6,646
Optum Health
Statement [Line Items]
Assets	80,400	$ 69,000
Goodwill	$ 5,900

Segment Financial Information_4

Segment Financial Information (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Statement [Line Items]
Premiums, revenues - unaffiliated customers	$ 72,786	$ 64,070
Investment and other income	798	367
Total revenues	91,931	80,149
Earnings from operations	8,086	6,950
Interest expense	(754)	(433)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	7,332	6,517
Products
Statement [Line Items]
Revenue from Products and Services - unaffiliated customers	10,267	9,340
Services
Statement [Line Items]
Revenue from Products and Services - unaffiliated customers	8,080	6,372
Optum
Statement [Line Items]
Investment and other income	343	224
Total revenues	54,059	43,259
Earnings from operations	3,743	3,152
Interest expense	0	0
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	3,743	3,152
Unaffiliated Customers
Statement [Line Items]
Premiums, revenues - unaffiliated customers	72,786	64,070
Total revenues	91,133	79,782
Unaffiliated Customers | Products
Statement [Line Items]
Revenue from Products and Services - unaffiliated customers	10,267	9,340
Unaffiliated Customers | Services
Statement [Line Items]
Revenue from Products and Services - unaffiliated customers	8,080	6,372
Unaffiliated Customers | Optum
Statement [Line Items]
Premiums, revenues - unaffiliated customers	5,328	4,133
Total revenues	21,120	17,330
Unaffiliated Customers | Optum | Products
Statement [Line Items]
Revenue from Products and Services - unaffiliated customers	10,267	9,340
Unaffiliated Customers | Optum | Services
Statement [Line Items]
Revenue from Products and Services - unaffiliated customers	5,525	3,857
Affiliated Customers
Statement [Line Items]
Total revenues	0	0
Affiliated Customers | Optum
Statement [Line Items]
Total revenues	32,596	25,705
Operating Segments | UnitedHealthcare
Statement [Line Items]
Investment and other income	455	143
Total revenues	70,468	62,595
Earnings from operations	4,343	3,798
Interest expense	0	0
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	4,343	3,798
Operating Segments | Optum Health
Statement [Line Items]
Investment and other income	277	156
Total revenues	23,004	16,682
Earnings from operations	1,776	1,366
Interest expense	0	0
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	1,776	1,366
Operating Segments | Optum Insight
Statement [Line Items]
Investment and other income	20	67
Total revenues	4,496	3,219
Earnings from operations	907	847
Interest expense	0	0
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	907	847
Operating Segments | Optum Rx
Statement [Line Items]
Investment and other income	46	1
Total revenues	27,418	23,911
Earnings from operations	1,060	939
Interest expense	0	0
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	1,060	939
Operating Segments | Unaffiliated Customers | UnitedHealthcare
Statement [Line Items]
Premiums, revenues - unaffiliated customers	67,458	59,937
Total revenues	70,013	62,452
Operating Segments | Unaffiliated Customers | UnitedHealthcare | Products
Statement [Line Items]
Revenue from Products and Services - unaffiliated customers	0	0
Operating Segments | Unaffiliated Customers | UnitedHealthcare | Services
Statement [Line Items]
Revenue from Products and Services - unaffiliated customers	2,555	2,515
Operating Segments | Unaffiliated Customers | Optum Health
Statement [Line Items]
Premiums, revenues - unaffiliated customers	5,328	4,133
Total revenues	8,461	6,697
Operating Segments | Unaffiliated Customers | Optum Health | Products
Statement [Line Items]
Revenue from Products and Services - unaffiliated customers	44	6
Operating Segments | Unaffiliated Customers | Optum Health | Services
Statement [Line Items]
Revenue from Products and Services - unaffiliated customers	3,089	2,558
Operating Segments | Unaffiliated Customers | Optum Insight
Statement [Line Items]
Premiums, revenues - unaffiliated customers	0	0
Total revenues	1,966	1,014
Operating Segments | Unaffiliated Customers | Optum Insight | Products
Statement [Line Items]
Revenue from Products and Services - unaffiliated customers	40	40
Operating Segments | Unaffiliated Customers | Optum Insight | Services
Statement [Line Items]
Revenue from Products and Services - unaffiliated customers	1,926	974
Operating Segments | Unaffiliated Customers | Optum Rx
Statement [Line Items]
Premiums, revenues - unaffiliated customers	0	0
Total revenues	10,693	9,619
Operating Segments | Unaffiliated Customers | Optum Rx | Products
Statement [Line Items]
Revenue from Products and Services - unaffiliated customers	10,183	9,294
Operating Segments | Unaffiliated Customers | Optum Rx | Services
Statement [Line Items]
Revenue from Products and Services - unaffiliated customers	510	325
Operating Segments | Affiliated Customers | UnitedHealthcare
Statement [Line Items]
Total revenues	0	0
Operating Segments | Affiliated Customers | Optum Health
Statement [Line Items]
Total revenues	14,266	9,829
Operating Segments | Affiliated Customers | Optum Insight
Statement [Line Items]
Total revenues	2,510	2,138
Operating Segments | Affiliated Customers | Optum Rx
Statement [Line Items]
Total revenues	16,679	14,291
Optum Eliminations
Statement [Line Items]
Investment and other income	0	0
Total revenues	(859)	(553)
Earnings from operations	0	0
Interest expense	0	0
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	0	0
Optum Eliminations | Unaffiliated Customers
Statement [Line Items]
Premiums, revenues - unaffiliated customers	0	0
Total revenues	0	0
Optum Eliminations | Unaffiliated Customers | Products
Statement [Line Items]
Revenue from Products and Services - unaffiliated customers	0	0
Optum Eliminations | Unaffiliated Customers | Services
Statement [Line Items]
Revenue from Products and Services - unaffiliated customers	0	0
Optum Eliminations | Affiliated Customers
Statement [Line Items]
Total revenues	(859)	(553)
Corporate and Eliminations
Statement [Line Items]
Investment and other income	0	0
Total revenues	(32,596)	(25,705)
Earnings from operations	0	0
Interest expense	(754)	(433)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	(754)	(433)
Corporate and Eliminations | Unaffiliated Customers
Statement [Line Items]
Premiums, revenues - unaffiliated customers	0	0
Total revenues	0	0
Corporate and Eliminations | Unaffiliated Customers | Products
Statement [Line Items]
Revenue from Products and Services - unaffiliated customers	0	0
Corporate and Eliminations | Unaffiliated Customers | Services
Statement [Line Items]
Revenue from Products and Services - unaffiliated customers	0	0
Corporate and Eliminations | Affiliated Customers
Statement [Line Items]
Total revenues	$ (32,596)	$ (25,705)